CMXHF - CSL Limited
CSL Limited
45 Poplar Road
Parkville, VIC 3052
Australia
61 3 9389 1911
https://www.csl.com.au
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 30 000
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Dr. Paul F. McKenzie Ph.D. | MD, CEO & Exec. Director | 2,32M | S.O. | 1966 |
| Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI | Chief Financial Officer | 2,15M | S.O. | 1965 |
| Mr. Paul R. Perreault B.A. | Strategic Advisor | 4,87M | S.O. | 1957 |
| Mr. Mark Dehring | Head of Investor Relations | S.O. | S.O. | S.O. |
| Mr. Gregory Boss B.S., BS(Hons), J.D. | Exec. VP of Legal & Group Gen. Counsel | S.O. | S.O. | 1961 |
| Christina Hickie | Sr. Mang. of Communications | S.O. | S.O. | S.O. |
| Ms. Elizabeth Walker B.A., M.S. | Exec. VP & Chief HR Officer | S.O. | S.O. | 1970 |
| Dr. Karen Etchberger | Exec. VP of Quality & Bus. Services | S.O. | S.O. | 1958 |
| Ms. Jemimah Brennan | Head of Communications - Asia Pacific | S.O. | S.O. | S.O. |
| Mr. William Campbell B.S. | Exec. VP & Chief Commercial Officer | S.O. | S.O. | 1960 |
Description
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Gouvernance d’entreprise
L’ISS Governance QualityScore de CSL Limited en date du 1 mai 2023 est 3. Les scores principaux sont Audit : 3; Société : 4; Droits des actionnaires : 1; Compensation : 5.
